Floatz logo

mk-3795

RCC

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

297 Active assets in the RCC cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

mk-3795 is also rated in:

nonpapillary renal cell carcinomaDormant
B
Indicative ·
58 / 100
View asset →
kidney cancerDormant
C
Indicative ·
39 / 100
View asset →
von Hippel-Lindau diseaseDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →